Expand the GABA-A modulator pipeline through the second asset
February 03, 2021 01:00 AM Eastern Standard Time
HONG KONG--( BUSINESS WIRE )--Engrail Therapeutics™ (Engrail) (the company) today announced the acquisition of the biomedical company NeuroCycle Therapeutics, which is committed to the development of the inhibitory neurotransmitter GABA in the human brain -A receptor, this acquisition continues to consolidate Engrail's leading position in the GABA-A field and provides a powerful platform for multiple ongoing clinical trials in 2021.
Dr. Vikram Sudarsan, CEO and President of Engrail Therapeutics said: “Engrail’s flexible trading model and “scientific first” approach allow us to obtain high-quality assets through a lower-risk market approach. At the same time, we fully integrate clinical Developed strategies, regulatory regulations, and a comprehensive understanding of intellectual property rights, so as to find differential assets with proven mechanisms of action. The effects of GABA-A have been fully verified, and this neurotransmitter modulator can be used in a wide range of neurology and Play a therapeutic role in psychiatric disorders. We now have a variety of BA-A modulators with powerful properties and look forward to rapid development.”
Dr. Vikram Sudarsan continued: "We will continue to be committed to building a leading and patient-centric neuroscience company, and continue to grow through patent licensing, joint development and acquisition channels. Our goal is to build a diverse Neuroscience treatment methods. The acquisition of NeuroCycle represents an important part of our development path. We expect 2021 to be a busy year as we plan to add more transactions to expand our asset portfolio."
Dr. Jed Hubbs, President of NeuroCycle, said: "NeuroCycle has always focused on the GABA-A space and has extensive experience. The acquisition of Engrail will inherit the work already carried out by NeuroCycle. We are convinced that this is definitely an ideal company model. At the same time, we look forward to seeing Engrail. Bring new drugs to patients in need."
About Engrail Therapeutics
Established in 2019, Engrail is committed to opening up new directions to reduce the pressure on patients and society from neurological diseases. We combine biological insights with feasible clinical solutions to build and advance a variety of transformative drug combinations. We use rigorous scientific methods to determine the most potential treatment methods, and use flexible trading models to promote those assets whose mechanism of action has been proven, and effectively transform them into commercial products. Engrail provides long-term capital commitments by Nan Fung Life Technology . For more information, please visit www.engrail.com .
Flare Communications Limited
Grace Chu
Email: grace.chu@flare.hk
Telephone: +852 3521 1560
